These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1299 related articles for article (PubMed ID: 15139787)

  • 21. How effective are the usual treatments for Crohn's disease?
    Bebb JR; Scott BB
    Aliment Pharmacol Ther; 2004 Jul; 20(2):151-9. PubMed ID: 15233694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative tolerability of treatments for inflammatory bowel disease.
    Stein RB; Hanauer SB
    Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.
    Panaccione R;
    Can J Gastroenterol; 2001 Jun; 15(6):371-5. PubMed ID: 11429666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
    Ruemmele FM; Veres G; Kolho KL; Griffiths A; Levine A; Escher JC; Amil Dias J; Barabino A; Braegger CP; Bronsky J; Buderus S; Martín-de-Carpi J; De Ridder L; Fagerberg UL; Hugot JP; Kierkus J; Kolacek S; Koletzko S; Lionetti P; Miele E; Navas López VM; Paerregaard A; Russell RK; Serban DE; Shaoul R; Van Rheenen P; Veereman G; Weiss B; Wilson D; Dignass A; Eliakim A; Winter H; Turner D; ;
    J Crohns Colitis; 2014 Oct; 8(10):1179-207. PubMed ID: 24909831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.
    Akobeng AK; Zachos M
    Cochrane Database Syst Rev; 2004; 2003(1):CD003574. PubMed ID: 14974022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
    Chauvin A; Le Thuaut A; Belhassan M; Le Baleur Y; Mesli F; Bastuji-Garin S; Delchier JC; Amiot A
    Dig Liver Dis; 2014 Aug; 46(8):695-700. PubMed ID: 24893686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.
    Sandborn WJ; Hanauer SB
    Am J Gastroenterol; 2002 Dec; 97(12):2962-72. PubMed ID: 12492177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
    Clemett D; Markham A
    Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corticosteroid-sparing treatments in patients with Crohn's disease.
    Plevy SE
    Am J Gastroenterol; 2002 Jul; 97(7):1607-17. PubMed ID: 12135008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medical therapy of inflammatory bowel diseases: Crohn's disease].
    Lakatos L; Lakatos PL
    Orv Hetil; 2007 Jun; 148(24):1107-14. PubMed ID: 17561480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.
    Schröder O; Blumenstein I; Schulte-Bockholt A; Stein J
    Aliment Pharmacol Ther; 2004 Feb; 19(3):295-301. PubMed ID: 14984376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic implications of biological therapies for Crohn's disease: review of infliximab.
    Bodger K
    Pharmacoeconomics; 2005; 23(9):875-88. PubMed ID: 16153132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis?
    Burakoff R
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S202-3. PubMed ID: 18816760
    [No Abstract]   [Full Text] [Related]  

  • 37. [Crohn's disease--standards of treatment 2004].
    Kruis W
    Praxis (Bern 1994); 2005 Oct; 94(41):1595-8. PubMed ID: 16245637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.
    Rutgeerts PJ
    Aliment Pharmacol Ther; 1999 Sep; 13 Suppl 4():9-15; discussion 38. PubMed ID: 10597334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: medical treatment of mild to moderately active Crohn's disease.
    Löfberg R
    Aliment Pharmacol Ther; 2003 Jun; 17 Suppl 2():18-22. PubMed ID: 12786608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 65.